Eric Hyllengren
Net worth: 147 630 $ as of 30/07/2026
Net worth: 147 630 $ as of 30/07/2026
Mr. Eric Hyllengren is a Chief Financial & Accounting Officer at Tenaya Therapeutics, Inc. Mr. Hyllengren was previously employed as a Chief Financial & Accounting Officer by Zura Bio Ltd., a Chief Financial, Operating & Accounting Officer by Atara Biotherapeutics, Inc., and an Executive Director-Business Development by Amgen, Inc. He received his undergraduate degree from the University of Notre Dame and an MBA from Kellogg School of Management.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 09/03/2026 | 17,617 ( 0.2% ) | 147 630 $ | 30/07/2026 |
| Companies | Position | Start |
|---|---|---|
| TENAYA THERAPEUTICS, INC. | Director of Finance/CFO | 12/07/2026 |
| Companies | Position | End |
|---|---|---|
| ZURA BIO LIMITED | Director of Finance/CFO | 19/04/2026 |
| ATARA BIOTHERAPEUTICS, INC. | Director of Finance/CFO | 30/03/2025 |
| AMGEN INC. | Corporate Officer/Principal | 31/12/2017 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 6 |
|---|---|
Amgen, Inc.
Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
University of Notre Dame
University of Notre Dame Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kellogg School of Management
Kellogg School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases | Health Technology |
Tenaya Therapeutics, Inc.
Tenaya Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for heart failure | Health Technology |
Zura Bio Ltd.
Zura Bio Ltd. BiotechnologyHealth Technology Operates as a multi-asset clinical-stage biotechnology company that focuses on develops novel medicines for immune and inflammatory disorders | Health Technology |
Select your edition
All financial news and data tailored to specific country editions